Compare CERT & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERT | SPTX |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2020 | 2026 |
| Metric | CERT | SPTX |
|---|---|---|
| Price | $8.42 | $24.25 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 106.4K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,838,000.00 | N/A |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | $5.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $4.45 | $17.59 |
| 52 Week High | $13.88 | $26.32 |
| Indicator | CERT | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.31 | 65.81 |
| Support Level | $7.94 | $18.72 |
| Resistance Level | $9.93 | N/A |
| Average True Range (ATR) | 0.37 | 1.44 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 83.04 | 70.22 |
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.